Sweet proteins (brazzein, thaumatin, monellin)

Sweet-protein biotech uses precision fermentation to produce intensely sweet, calorie-free proteins — brazzein, thaumatin, monellin and engineered variants — as sugar replacements, moving the category off its historical reliance on plant extraction. Oobli, based in Davis, California, describes itself as the first and only commercial-scale sweet-protein technology platform and received its third FDA “no questions” letter in September 2025 for its brazzein-based sweetening ingredient, following that with an Andean regional manufacturing partnership announced in April 2026 with Magdalena, a sugar producer diversifying into high-value molecules. In Lithuania, Pentasweet broke ground in March 2026 on a €65 million ($76 million) precision fermentation facility in Vilnius — described as Europe’s first commercial-scale sweet-protein factory — with brazzein production expected to begin in the first half of 2027. In Israel, Amai Proteins' engineered sweet protein sweelin received FDA GRAS clearance in February 2026 and Singapore Food Agency approval in May 2026, with clinical trial results published in the journal Food Chemistry confirming blood-glucose safety. And in Finland, the VTT Technical Research Centre engineered Trichoderma reesei fungal strains to express brazzein at approximately 1.3 g/L in bioreactor culture — several-fold higher than prior E. coli or yeast systems — estimating a production cost that could fall to €57–80 per kilogram. Of the catalog’s three named proteins, confirmed live-source activity in this pass concentrates on brazzein; thaumatin’s plant-molecular-farming route is already covered by a sibling article’s Nomad Bioscience entry, and monellin appears in this pass only in general academic reviews of microbial sweet-protein expression, without a confirmed dedicated commercial originator.

The key directions of sweet-protein biotech are:

1. Precision-fermented brazzein production (Precision-Fermented Brazzein Production): yeast or fungal hosts engineered to express and secrete brazzein at commercial-scale titers, replacing extraction from the West African oubli fruit.
2. Engineered next-generation sweet proteins (Engineered Next-Generation Sweet Proteins): designed protein variants optimized for taste profile and stability beyond any single natural sweet protein.
3. Regulatory clearance as a market gate (Regulatory Clearance as a Market Gate): FDA “no questions”/GRAS letters and country-specific food-additive approvals functioning as the primary commercialization bottleneck ahead of scale-up.
4. High-titer expression-host engineering (High-Titer Expression-Host Engineering): strain screening and promoter optimization (in Komagataella phaffii, Pichia pastoris, Trichoderma reesei) to raise sweet-protein bioreactor yields and cut production cost.

Sectoral value chain#

[expression-host engineering] ──> [fermentation] ──> [protein purification] ──> [regulatory clearance]
                                                                              │
                                                                       (taste/stability
                                                                        validation)
                                                                              │
                                                                              ▼
[food/beverage formulation & sale] <─── [ingredient formulation] <─────────────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• High-titer strain screening (High-Titer Strain Screening): selection methods (e.g., zeocin-based screening) identifying production clones with elevated sweet-protein yield.
• Fungal/yeast secretion engineering (Fungal/Yeast Secretion Engineering): promoter and expression-system choices (synthetic expression systems, native cbh1 promoter) tuned for extracellular sweet-protein secretion.
• Sweet-protein taste/stability optimization (Sweet-Protein Taste/Stability Optimization): protein engineering targeting off-notes, heat stability and pH tolerance for food and beverage applications.

The stack pairs high-titer expression-host engineering with the regulatory clearance work needed to reach food and beverage shelves.

1. High-titer fungal/yeast expression engineering (High-Titer Fungal/Yeast Expression Engineering):
   • strain screening and promoter selection raise sweet-protein secretion titers well above earlier bacterial or yeast baselines.
   • case: VTT’s synthetic expression system in Trichoderma reesei reached ~1.3 g/L brazzein in bioreactor culture, several-fold above prior E. coli/yeast results, at an estimated €57–80/kg production cost.
2. Engineered next-generation sweet-protein design (Engineered Next-Generation Sweet-Protein Design):
   • protein engineering beyond a single natural sequence targets improved taste profile, stability and regulatory-ready safety data.
   • case: Amai Proteins’ sweelin cleared FDA GRAS and Singapore Food Agency approval, backed by published clinical blood-glucose safety data.
3. Regulatory-clearance-gated commercial scale-up (Regulatory-Clearance-Gated Commercial Scale-Up):
   • repeated regulatory clearances de-risk investment in dedicated commercial-scale fermentation capacity.
   • case: Oobli’s third FDA no-questions letter preceded its Andean manufacturing partnership; Pentasweet’s Vilnius facility represents Europe’s first commercial-scale build-out for the category.